ArticleCancer medicine2023

Impact of residual disease biomarkers on the prognosis of HER2-positive breast cancer following neoadjuvant therapy.

Youzhao Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.